Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Antagonistic effects of the staphylococcal enterotoxin a mutant, SEA(F47A/D227A), on psoriasis in the SCID-hu xenogeneic transplantation model.

Boehncke WH, Hardt-Weinelt K, Nilsson H, Wolter M, Dohlsten M, Ochsendorf FR, Kaufmann R, Antonsson P.

J Invest Dermatol. 2001 Apr;116(4):596-601.

2.

T-cell function and migration. Two sides of the same coin.

von Andrian UH, Mackay CR.

N Engl J Med. 2000 Oct 5;343(14):1020-34. Review. No abstract available.

PMID:
11018170
3.

Is psoriasis a T-cell disease?

Nickoloff BJ, Schröder JM, von den Driesch P, Raychaudhuri SP, Farber EM, Boehncke WH, Morhenn VB, Rosenberg EW, Schön MP, Holick MF.

Exp Dermatol. 2000 Oct;9(5):359-75.

PMID:
11016857
4.

Proteasome inhibition measurements: clinical application.

Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ.

Clin Chem. 2000 May;46(5):673-83.

5.

Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519.

Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD.

J Autoimmun. 2000 May;14(3):205-11.

PMID:
10756082
6.
8.

Inflammatory skin diseases, T cells, and immune surveillance.

Robert C, Kupper TS.

N Engl J Med. 1999 Dec 9;341(24):1817-28. Review. No abstract available.

PMID:
10588968
9.

The SCID-hu xenogeneic transplantation model: complex but telling.

Boehncke WH.

Arch Dermatol Res. 1999 Jul-Aug;291(7-8):367-73. Review.

PMID:
10482004
10.

CD69 and regulation of the immune function.

Marzio R, Mauël J, Betz-Corradin S.

Immunopharmacol Immunotoxicol. 1999 Aug;21(3):565-82. Review.

PMID:
10466080
11.

Proteasome inhibition: A novel mechanism to combat asthma.

Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J.

J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):294-300.

PMID:
10452747
12.

Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis.

Nickoloff BJ, Wrone-Smith T.

Am J Pathol. 1999 Jul;155(1):145-58.

13.

Animal models of psoriasis - what can we learn from them?

Schön MP.

J Invest Dermatol. 1999 Apr;112(4):405-10. Review.

14.

The SCID-hu xenogeneic transplantation model allows screening of anti-psoriatic drugs.

Boehncke WH, Kock M, Hardt-Weinelt K, Wolter M, Kaufmann R.

Arch Dermatol Res. 1999 Feb-Mar;291(2-3):104-6. No abstract available.

PMID:
10195398
15.

Evidence for superantigen involvement in skin homing of T cells in atopic dermatitis.

Strickland I, Hauk PJ, Trumble AE, Picker LJ, Leung DY.

J Invest Dermatol. 1999 Feb;112(2):249-53.

16.

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.

Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, Wolf RE, Huang J, Brand S, Elliott PJ, Lazarus D, McCormack T, Parent L, Stein R, Adams J, Grisham MB.

Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15671-6.

17.

New twists in gene regulation by glucocorticoid receptor: is DNA binding dispensable?

Karin M.

Cell. 1998 May 15;93(4):487-90. Review. No abstract available.

18.

The proteasome: paradigm of a self-compartmentalizing protease.

Baumeister W, Walz J, Zühl F, Seemüller E.

Cell. 1998 Feb 6;92(3):367-80. Review. No abstract available.

19.

Superantigens but not mitogens are capable of inducing upregulation of E-selectin ligands on human T lymphocytes.

Zollner TM, Nuber V, Duijvestijn AM, Boehncke WH, Kaufmann R.

Exp Dermatol. 1997 Aug;6(4):161-6.

PMID:
9293387
20.

Identification and characterization of an IkappaB kinase.

Régnier CH, Song HY, Gao X, Goeddel DV, Cao Z, Rothe M.

Cell. 1997 Jul 25;90(2):373-83.

Supplemental Content

Support Center